PERP_B: Q2 2025 sales up 165%, losses reduced, major acquisition and asset sale boost outlook

About this update from Perpetua Medical Ab Class B

Net sales surged 165% in Q2 2025, driven by ES-Medical, while operating losses narrowed significantly. Acquisition activity is accelerating, with a major deal in progress and legacy assets divested for 10 MSEK. Financing is secured via a 25 MSEK facility.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Perpetua Medical Ab Class B